{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:07:29Z","timestamp":1783163249737,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Myasthenia gravis (MG) is a rare neuromuscular disorder. Symptoms can range from ptosis only to life threatening myasthenic crisis. Thymectomy is recommended for anti-acetylcholine receptor-antibody positive patients with early-onset MG. Here, we investigated prognostic factors shaping therapeutic outcomes of thymectomy to improve patient stratification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively collected single-center data from a specialized center for MG from all consecutive adult patients that underwent thymectomy from 01\/2012 to 12\/2020. We selected patients with thymoma-associated and non-thymomatous MG for further investigations. We analyzed the patient collective regarding perioperative parameters in relation to the surgical approach. Furthermore, we investigated the dynamics of the anti-acetylcholine receptor-antibody titers and concurrent immunosuppressive therapies, as well as the therapeutic outcomes in dependence of clinical classifications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 137 patients 94 were included for further analysis. We used a minimally invasive approach in 73 patients, whereas 21 patients underwent sternotomy. A total of 45 patients were classified as early-onset MG (EOMG), 28 as late-onset MG (LOMG) and 21 as thymoma-associated MG (TAMG). The groups differed in terms of age at diagnosis (EOMG: 31.1\u2009\u00b1\u200912.2 years; LOMG: 59.8\u2009\u00b1\u200913.7 years; TAMG: 58.6\u2009\u00b1\u200916.7 years; p\u2009&lt;\u20090.001). Patients with EOMG and TAMG were more often female than patients in the LOMG group (EOMG: 75.6%; LOMG: 42.9%; TAMG: 61.9%; p\u2009=\u20090.018). There were no significant differences in outcome scores (quantitative MG; MG activities of daily living; MG Quality of Live) with a median follow-up of 46 months. However, Complete Stable Remission was achieved significantly more frequently in the EOMG group than in the other two groups (p\u2009=\u20090.031). At the same time, symptoms seem to improve similarly in all three groups (p\u2009=\u20090.25).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study confirms the benefit of thymectomy in the therapy of MG. Both, the concentration of acetylcholine receptor antibodies and the necessary dosage of cortisone therapy show a continuous regression after thymectomy in the overall cohort. Beyond EOMG, groups of LOMG and thymomatous MG responded to thymectomy as well, but therapy success was less pronounced and delayed compared to the EOMG subgroup. Thymectomy is a mainstay of MG therapy to be considered in all subgroups of MG patients investigated.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s42466-023-00252-w","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:03:53Z","timestamp":1686787433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The impact of thymectomy in subgroups of Myasthenia gravis patients: a single center longitudinal observation"],"prefix":"10.1186","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-2804","authenticated-orcid":false,"given":"Hruy","family":"Menghesha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Nelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schlachtenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Welskop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Camo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Heldwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardus","family":"Bennink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Wahlers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Servet","family":"B\u00f6l\u00fckbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Doerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khosro","family":"Hekmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"4","key":"252_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000431036","volume":"44","author":"MI Boldingh","year":"2015","unstructured":"Boldingh, M. I., et al. (2015). Geographical distribution of myasthenia gravis in northern europe-results from a population-based study from two countries. Neuroepidemiology, 44(4), 221\u2013231.","journal-title":"Neuroepidemiology"},{"issue":"1","key":"252_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr, A. S., et al. (2010). A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC neurology, 10(1), 1\u20139.","journal-title":"BMC neurology"},{"issue":"25","key":"252_CR3","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","volume":"330","author":"D DB","year":"1994","unstructured":"DB, D. (1994). Myasthenia gravis. New England Journal Of Medicine, 330(25), 1797\u20131810.","journal-title":"New England Journal Of Medicine"},{"key":"252_CR4","doi-asserted-by":"crossref","unstructured":"Kaminski, H. J., & Kusner, L. L. (2009). Myasthenia gravis and related disorders. Springer.","DOI":"10.1007\/978-1-59745-156-7"},{"issue":"2","key":"252_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","volume":"21","author":"JJ Verschuuren","year":"2022","unstructured":"Verschuuren, J. J., et al. (2022). Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. The Lancet Neurology, 21(2), 189\u2013202.","journal-title":"The Lancet Neurology"},{"issue":"2","key":"252_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/CCO.0b013e32834ea6bb","volume":"24","author":"L Spaggiari","year":"2012","unstructured":"Spaggiari, L., Casiraghi, M., & Guarize, J. (2012). Multidisciplinary treatment of malignant thymoma. Current Opinion In Oncology, 24(2), 117\u2013122.","journal-title":"Current Opinion In Oncology"},{"issue":"10","key":"252_CR7","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1212\/WNL.33.10.1276","volume":"33","author":"A Vincent","year":"1983","unstructured":"Vincent, A., et al. (1983). Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis. Neurology, 33(10), 1276\u20131276.","journal-title":"Neurology"},{"issue":"6","key":"252_CR8","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe, G. I., et al. (2016). Randomized trial of thymectomy in myasthenia gravis. New England Journal of Medicine, 375(6), 511\u2013522.","journal-title":"New England Journal of Medicine"},{"key":"252_CR9","unstructured":"Schumacher, E. D., & Roth, O. (1912). Thymektomie bei einem fall von morbus Basedowi mit myasthenie. G. Fischer."},{"issue":"3","key":"252_CR10","first-page":"478","volume":"57","author":"F Li","year":"2020","unstructured":"Li, F., et al. (2020). Thymectomy in ocular myasthenia gravis before generalization results in a higher remission rate. European Journal of Cardio-Thoracic Surgery, 57(3), 478\u2013487.","journal-title":"European Journal of Cardio-Thoracic Surgery"},{"issue":"4","key":"252_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00415-015-7673-z","volume":"262","author":"A Uzawa","year":"2015","unstructured":"Uzawa, A., et al. (2015). Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis. Journal of neurology, 262(4), 1019\u20131023.","journal-title":"Journal of neurology"},{"issue":"3","key":"252_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1600-0404.2006.00733.x","volume":"115","author":"H Yuan","year":"2007","unstructured":"Yuan, H., et al. (2007). The effectiveness of thymectomy on seronegative generalized myasthenia gravis: Comparing with seropositive cases. Acta neurologica scandinavica, 115(3), 181\u2013184.","journal-title":"Acta neurologica scandinavica"},{"issue":"3","key":"252_CR13","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.athoracsur.2019.02.016","volume":"108","author":"F Li","year":"2019","unstructured":"Li, F., et al. (2019). Results of robotic thymectomy performed in myasthenia gravis patients older than 60 years at onset. The Annals of Thoracic Surgery, 108(3), 912\u2013919.","journal-title":"The Annals of Thoracic Surgery"},{"issue":"18","key":"252_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1001\/jama.1941.02820440037009","volume":"117","author":"A Blalock","year":"1941","unstructured":"Blalock, A., et al. (1941). The treatment of myasthenia gravis by removal of the thymus gland: Preliminary report. Journal of the American Medical Association, 117(18), 1529\u20131533.","journal-title":"Journal of the American Medical Association"},{"issue":"1","key":"252_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1212\/WNL.32.1.83","volume":"32","author":"A Masaoka","year":"1982","unstructured":"Masaoka, A., et al. (1982). Reoperation after transcervical thymectomy for myasthenia gravis. Neurology, 32(1), 83\u201383.","journal-title":"Neurology"},{"issue":"1","key":"252_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/0002-9343(83)91122-1","volume":"74","author":"M Rosenberg","year":"1983","unstructured":"Rosenberg, M., et al. (1983). Recurrence of thymic hyperplasia after thymectomy in myasthenia gravis: Its importance as a cause of failure of surgical treatment. The American journal of medicine, 74(1), 78\u201382.","journal-title":"The American journal of medicine"},{"issue":"3","key":"252_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/14017438409109897","volume":"18","author":"A Henze","year":"1984","unstructured":"Henze, A., et al. (1984). Failing transcervical thymectomy in myasthenia gravis: An evaluation of transsternal re-exploration. Scandinavian journal of thoracic and cardiovascular surgery, 18(3), 235\u2013238.","journal-title":"Scandinavian journal of thoracic and cardiovascular surgery"},{"issue":"2","key":"252_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.athoracsur.2004.02.021","volume":"78","author":"M Zieli\u0144ski","year":"2004","unstructured":"Zieli\u0144ski, M., et al. (2004). Transcervical-subxiphoid-videothoracoscopic \u201cmaximal\u201d thymectomy\u2014operative technique and early results. The Annals of thoracic surgery, 78(2), 404\u2013409.","journal-title":"The Annals of thoracic surgery"},{"issue":"10","key":"252_CR19","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus, N. E., & Verschuuren, J. J. (2015). Myasthenia gravis: Subgroup classification and therapeutic strategies. The Lancet Neurology, 14(10), 1023\u20131036.","journal-title":"The Lancet Neurology"},{"issue":"7","key":"252_CR20","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.nmd.2021.05.006","volume":"31","author":"AM Ruiter","year":"2021","unstructured":"Ruiter, A. M., et al. (2021). Accuracy of patient-reported data for an online patient registry of autoimmune myasthenia gravis and Lambert-Eaton myasthenic syndrome. Neuromuscular Disorders, 31(7), 622\u2013632.","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"252_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-022-02448-4","volume":"19","author":"C Nelke","year":"2022","unstructured":"Nelke, C., et al. (2022). Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. Journal of neuroinflammation, 19(1), 1\u201312.","journal-title":"Journal of neuroinflammation"},{"issue":"5","key":"252_CR22","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/icvts\/ivv176","volume":"21","author":"Z Liu","year":"2015","unstructured":"Liu, Z., et al. (2015). Unilateral video-assisted thoracoscopic extended thymectomy offers long-term outcomes equivalent to that of the bilateral approach in the treatment of non-thymomatous myasthenia gravis. Interactive CardioVascular and Thoracic Surgery, 21(5), 610\u2013615.","journal-title":"Interactive CardioVascular and Thoracic Surgery"},{"issue":"2","key":"252_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0003-4975(02)03722-0","volume":"74","author":"JB Shrager","year":"2002","unstructured":"Shrager, J. B., et al. (2002). Transcervical thymectomy for myasthenia gravis achieves results comparable to thymectomy by sternotomy. The Annals of thoracic surgery, 74(2), 320\u2013327.","journal-title":"The Annals of thoracic surgery"},{"issue":"Suppl 5","key":"252_CR24","doi-asserted-by":"publisher","first-page":"52S","DOI":"10.1212\/WNL.48.Suppl_5.52S","volume":"48","author":"A Jaretzki","year":"1997","unstructured":"Jaretzki, A. (1997). Thymectomy for myasthenia gravis: Analysis of the controversies regarding technique and results. Neurology, 48(Suppl 5), 52S\u201363S.","journal-title":"Neurology"},{"issue":"2","key":"252_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.21037\/acs.2019.02.04","volume":"8","author":"KE O\u2019Sullivan","year":"2019","unstructured":"O\u2019Sullivan, K. E., et al. (2019). A systematic review of robotic versus open and video assisted thoracoscopic surgery (VATS) approaches for thymectomy. Annals of cardiothoracic surgery, 8(2), 174.","journal-title":"Annals of cardiothoracic surgery"},{"issue":"6","key":"252_CR26","first-page":"5","volume":"34","author":"J Cooper","year":"1989","unstructured":"Cooper, J., et al. (1989). Symposium: Thymectomy for myasthenia gravis. Contemp Surg, 34(6), 5\u201386.","journal-title":"Contemp Surg"},{"issue":"5","key":"252_CR27","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ejcts.2003.08.002","volume":"24","author":"M De Perrot","year":"2003","unstructured":"De Perrot, M., et al. (2003). Impact of minimally invasive trans-cervical thymectomy on outcome in patients with myasthenia gravis. European journal of cardio-thoracic surgery, 24(5), 677\u2013683.","journal-title":"European journal of cardio-thoracic surgery"},{"issue":"3","key":"252_CR28","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","volume":"76","author":"K Kondo","year":"2003","unstructured":"Kondo, K., & Monden, Y. (2003). Therapy for thymic epithelial tumors: A clinical study of 1,320 patients from Japan. The Annals of thoracic surgery, 76(3), 878\u2013884.","journal-title":"The Annals of thoracic surgery"},{"issue":"5","key":"252_CR29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1093\/ejcts\/ezz334","volume":"57","author":"KJ Na","year":"2020","unstructured":"Na, K. J., et al. (2020). Predictors of post-thymectomy long-term neurological remission in thymomatous myasthenia gravis: An analysis from a multi-institutional database. European Journal of Cardio-Thoracic Surgery, 57(5), 867\u2013873.","journal-title":"European Journal of Cardio-Thoracic Surgery"},{"issue":"3","key":"252_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami, P., et al. (2021). International consensus guidance for management of myasthenia gravis: 2020 update. Neurology, 96(3), 114\u2013122.","journal-title":"Neurology"},{"issue":"6","key":"252_CR31","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0003-4975(99)00167-8","volume":"67","author":"M Tsuchida","year":"1999","unstructured":"Tsuchida, M., et al. (1999). Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. The Annals of thoracic surgery, 67(6), 1563\u20131567.","journal-title":"The Annals of thoracic surgery"},{"issue":"6","key":"252_CR32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"D Sanders","year":"2008","unstructured":"Sanders, D., et al. (2008). An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology, 71(6), 400\u2013406.","journal-title":"Neurology"},{"issue":"4","key":"252_CR33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamaneurol.2020.5407","volume":"78","author":"T Sharshar","year":"2021","unstructured":"Sharshar, T., et al. (2021). Comparison of corticosteroid tapering regimens in myasthenia gravis: A randomized clinical trial. JAMA neurology, 78(4), 426\u2013433.","journal-title":"JAMA neurology"},{"key":"252_CR34","doi-asserted-by":"publisher","first-page":"175628642093569","DOI":"10.1177\/1756286420935697","volume":"13","author":"F Aguirre","year":"2020","unstructured":"Aguirre, F., et al. (2020). C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis. Therapeutic Advances in Neurological Disorders, 13, 1756286420935697.","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"4","key":"252_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/CND.0b013e31824619d5","volume":"13","author":"C Barnett","year":"2012","unstructured":"Barnett, C., et al. (2012). The quantitative myasthenia gravis score: Comparison with clinical, electrophysiological, and laboratory markers. Journal of clinical neuromuscular disease, 13(4), 201\u2013205.","journal-title":"Journal of clinical neuromuscular disease"},{"issue":"9","key":"252_CR36","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/jnnp-2012-302705","volume":"83","author":"T Masuda","year":"2012","unstructured":"Masuda, T., et al. (2012). Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. Journal of Neurology Neurosurgery & Psychiatry, 83(9), 935\u2013940.","journal-title":"Journal of Neurology Neurosurgery & Psychiatry"},{"issue":"2","key":"252_CR37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/aian.AIAN_243_19","volume":"23","author":"D Vemuri","year":"2020","unstructured":"Vemuri, D., et al. (2020). Disease severity assessment and short-term outcome in patients with myasthenia gravis. Annals of Indian Academy of Neurology, 23(2), 215.","journal-title":"Annals of Indian Academy of Neurology"},{"issue":"16","key":"252_CR38","doi-asserted-by":"publisher","first-page":"e1425","DOI":"10.1212\/WNL.0000000000005323","volume":"90","author":"K Hewett","year":"2018","unstructured":"Hewett, K., et al. (2018). Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology, 90(16), e1425\u2013e1434.","journal-title":"Neurology"},{"issue":"2","key":"252_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","volume":"14","author":"JF Liu","year":"2010","unstructured":"Liu, J. F., et al. (2010). Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Therapeutic Apheresis and Dialysis, 14(2), 153\u2013160.","journal-title":"Therapeutic Apheresis and Dialysis"},{"issue":"4","key":"252_CR40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/mus.26404","volume":"59","author":"KM Clifford","year":"2019","unstructured":"Clifford, K. M., et al. (2019). Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle & nerve, 59(4), 404\u2013410.","journal-title":"Muscle & nerve"},{"issue":"9","key":"252_CR41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/00207454.2016.1257993","volume":"127","author":"J Yang","year":"2017","unstructured":"Yang, J., et al. (2017). Prognosis of thymectomy in myasthenia gravis patients with thymus hyperplasia. International Journal of Neuroscience, 127(9), 785\u2013789.","journal-title":"International Journal of Neuroscience"},{"issue":"5\u20136","key":"252_CR42","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/08916930903518107","volume":"43","author":"DB Sanders","year":"2010","unstructured":"Sanders, D. B., & Evoli, A. (2010). Immunosuppressive therapies in myasthenia gravis. Autoimmunity, 43(5\u20136), 428\u2013435.","journal-title":"Autoimmunity"},{"key":"252_CR43","doi-asserted-by":"publisher","first-page":"175628642090420","DOI":"10.1177\/1756286420904207","volume":"13","author":"M Oyama","year":"2020","unstructured":"Oyama, M., et al. (2020). Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Therapeutic Advances in Neurological Disorders, 13, 1756286420904207.","journal-title":"Therapeutic Advances in Neurological Disorders"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-023-00252-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-023-00252-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-023-00252-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T03:09:11Z","timestamp":1702609751000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurolrespract.biomedcentral.com\/articles\/10.1186\/s42466-023-00252-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["252"],"URL":"https:\/\/doi.org\/10.1186\/s42466-023-00252-w","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"4 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The investigation has been conducted in accordance with the Declaration of Helsinki. Due to its retrospective character, the need for written informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors give their consent for the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"MS participates in the medical advisory board of the German Myasthenia Gravis Foundation (Deutsche Myasthenie Gesellschaft e.V.). Furthermore, MS und KH participate in the Steering group for the German guidelines on myasthenia gravis treatment. TR participates in the medical advisory board of the German Myasthenia Gravis Foundation (Deutsche Myasthenie Gesellschaft e.V.) and received honoraria for lecturing from Alexion, Argenx and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}